Enliven Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

• Enliven Therapeutics Inc ELVN.OQ reported a quarterly adjusted loss of 57 cents​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of -54 cents. The mean expectation of seven analysts for the quarter was for a loss of 50 cents per share. Wall Street expected results to range from -55 cents to -47 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Enliven Therapeutics Inc's reported EPS for the quarter was a loss of 57 cents​.

• The company reported a quarterly loss of $28.54 million.

• Enliven Therapeutics Inc shares had risen by 1.8% this quarter and lost 11.0% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 12.2% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• Wall Street's median 12-month price target for Enliven Therapeutics Inc is $39.00

This summary was machine generated from LSEG data May 14 at 08:35 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)